Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2000 December;41(6) > The Journal of Cardiovascular Surgery 2000 December;41(6):931-4

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES  THORACIC PAPERS 

The Journal of Cardiovascular Surgery 2000 December;41(6):931-4

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Management of ipsilateral intrapulmonary metastases in the new TNM system for non-small cell lung cancer

Kamiyoshihara M., Kawashima O., Sakata S., Hirai T., Ishikawa S., Morishita Y.

From the First Department of Surgery National Sanatorium Nishi-Gunma Hospital Shibukawa, Gunma, Japan *Second Department of Surgery Gunma University School of Medicine Maebashi, Gunma, Japan


PDF


Backgrounds. Recently, the Union Internationale Contre le Cancer and American Joint Committee on Cancer reclassified not only TNM staging but also ipsilateral intrapulmonary metastases (PM) as T4 in a same lobe or M1 in different lobes. To determine whether the new PM staging is appropriate, we studied the prognosis of PM.
Methods. From January 1981 to October 1997, we performed a lobectomy or pneumonectomy with mediastinal lymph node dissection, and had 42 patients with PM. We analyzed the postoperative prognosis of the patients with ipsilateral PM compared with the same stage group without PM (the non-PM).
Results. In the previous classification of PM (the old PM), 2 patients were categorized as stage IIA, 9 as IIB, 17 as IIIA, and 14 as IIIB. After reclassification (the new PM), 37 patients were categorized as stage IIIB, and 5 as IV. The old PM stage IIIA group had a significantly poor prognosis compared with the non-PM stage IIIA. However, the prognosis of the new PM group was compatible with that of the non-PM. None of the other staging group had a significant difference in the prognosis.
Conclusions. The management of PM in the new TNM system for non-small cell lung cancer is appropriate.

top of page